EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Toward the Implementation of Optimal Cardiac Magnetic Resonance Risk Stratification in Pulmonary Arterial Hypertension

Lucas R Celant, Jeroen N Wessels, J Tim Marcus, Lilian J Meijboom, Harm Jan Bogaard, Frances S de Man, Anton Vonk Noordegraaf

CHEST · 2024

DOI: 10.1016/j.chest.2023.07.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CHEST, 2024. Verfasst von Lucas R Celant und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, The Netherlands; Pulmonary Hypertension and Thrombosis, Amster…. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Hypertension, Pulmonary, Ventricular Dysfunction, Right. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Hartstichting, Koninklijke Nederlandse Academie van Wetenschappen, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The 2022 European Society of Cardiology/European Respiratory Society pulmonary hypertension (PH) guidelines incorporate cardiac magnetic resonance (CMR) imaging metrics in the risk stratification of patients with pulmonary arterial hypertension (PAH). Thresholds to identify patients at estimated 1-year mortality risks of 20% are introduced. However, these cutoff values are mostly single center-based and require external validation. RESEARCH QUESTION: What are the discriminative prognostic properties of the current CMR risk thresholds stratifying patients with PAH? STUDY DESIGN AND METHODS: We analyzed data from incident, treatment-naïve patients with PAH from the Amsterdam University Medical Centres, Vrije Universiteit, The Netherlands. The discriminative properties of the proposed CMR three risk strata were tested at baseline and first reassessment, using the following PH guideline variables: right ventricular ejection fraction, indexed right ventricular end-systolic volume, and indexed left ventricular stroke volume. RESULTS: A total of 258 patients with PAH diagnosed between 2001 and 2022 fulfilled the study criteria and were included in this study. Of these, 172 had follow-up CMR imaging after 3 months to 1.5 years. According to the CMR three risk strata, most patients were classified at intermediate risk (n = 115 [45%]) upon diagnosis. Only 29 (11%) of patients with PAH were classified at low risk, and 114 (44%) were classified at high risk. Poor survival discrimination was seen between risk groups. Appropriate survival discrimination was seen at first reassessment. INTERPRETATION: Risk stratifying patients with PAH with the recent proposed CMR cutoffs from the European Society of Cardiology/European Respiratory Society 2022 PH guidelines requires adjustment because post-processing consensus is lacking and general applicability is limited. Risk assessment at follow-up yielded better survival discrimination, emphasizing the importance of the individual treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionHypertension, PulmonaryVentricular Dysfunction, RightHumansStroke VolumeVentricular Function, RightMagnetic Resonance ImagingFamilial Primary Pulmonary HypertensionRisk AssessmentMagnetic Resonance Spectroscopy

Stichwörter der Autor:innen

cardiac magnetic resonancepulmonary arterial hypertensionright ventriclerisk stratification

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, The Netherlands; Pulmonary Hypertension and Thrombosis, Amsterdam Cardiovascular Sciences, Amsterdam UMC location Vrije Universiteit…
  • Pulmonary Hypertension and Thrombosis, Amsterdam Cardiovascular Sciences, Amsterdam UMC location Vrije Universiteit Amsterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije…

Förderung

  • Nederlandse Hartstichting
  • Koninklijke Nederlandse Academie van Wetenschappen
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • Nederlandse Federatie van Universitair Medische Centra
  • ZonMw
  • Janssen Pharmaceuticals

Zitieren

APA

Celant, L. R., Wessels, J. N., Marcus, J. T., Meijboom, L. J., Bogaard, H. J., de Man, F. S., & Vonk Noordegraaf, A. (2024). Toward the Implementation of Optimal Cardiac Magnetic Resonance Risk Stratification in Pulmonary Arterial Hypertension. CHEST. https://doi.org/10.1016/j.chest.2023.07.028

Vancouver

Celant LR, Wessels JN, Marcus JT, Meijboom LJ, Bogaard HJ, de Man FS, et al. Toward the Implementation of Optimal Cardiac Magnetic Resonance Risk Stratification in Pulmonary Arterial Hypertension. CHEST. 2024. doi:10.1016/j.chest.2023.07.028

BibTeX
@article{Celant2024,
  author = {Celant, Lucas R and Wessels, Jeroen N and Marcus, J Tim and Meijboom, Lilian J and Bogaard, Harm Jan and de Man, Frances S and Vonk Noordegraaf, Anton},
  title = {Toward the Implementation of Optimal Cardiac Magnetic Resonance Risk Stratification in Pulmonary Arterial Hypertension},
  journal = {CHEST},
  year = {2024},
  doi = {10.1016/j.chest.2023.07.028}
}
Kostenlos starten →